CAJ | 학술논문

目的：探讨阿托伐他汀早期强化治疗急性冠脉综合征(ACS)的近期临床疗效.方法：经临床、心电图或/和冠状动脉造影确认、症状出现48小时内的ACS患者为研究对象.58例ACS患者在接受常规治疗(包括溶栓剂、抗凝剂、ACEI、β受体阻滞剂、钙通道拮抗剂、硝酸酯类等)基础上,被随机均分为阿托伐他汀强化治疗组(40mg/日)与常规治疗组(20mg/日),用药时间5天.观察两组患者治疗前后血脂变化、治疗后1~2周内主要心血管事件发生情况及不良反应发生率.结果：阿托伐他汀早期强化治疗组较常规治疗组复发性心绞痛、心力衰竭、心律失常发生率均较常规治疗组明显降低(P均<0.05),两组未见严重不良反应.结论：阿托伐他汀早期强化治疗ACS,可明显降低治疗后1~2周内复发性心绞痛、心力衰竭、心律失常发生率,且治疗过程中无严重不良反应.
목적：탐토아탁벌타정조기강화치료급성관맥종합정(ACS)적근기림상료효.방법：경림상、심전도혹/화관상동맥조영학인、증상출현48소시내적ACS환자위연구대상.58례ACS환자재접수상규치료(포괄용전제、항응제、ACEI、β수체조체제、개통도길항제、초산지류등)기출상,피수궤균분위아탁벌타정강화치료조(40mg/일)여상규치료조(20mg/일),용약시간5천.관찰량조환자치료전후혈지변화、치료후1~2주내주요심혈관사건발생정황급불량반응발생솔.결과：아탁벌타정조기강화치료조교상규치료조복발성심교통、심력쇠갈、심률실상발생솔균교상규치료조명현강저(P균<0.05),량조미견엄중불량반응.결론：아탁벌타정조기강화치료ACS,가명현강저치료후1~2주내복발성심교통、심력쇠갈、심률실상발생솔,차치료과정중무엄중불량반응.
Objective:To determine the effect of primary intensive atrovastatin therapy in the treatment of ACS on clinical effect in the near future. Methods:ACS patients object of study were confirmed by clinical,electrocardioagram[EKG]or(and)coronary angiography,sympto-ms appears in 48 hours.58 ACS patients who received routine treatment (includes:thrombolytics,anticoagulant,ACEI,beta-blockers,calcum cha- nnel blockers,nitrates etc) were randomly into atrovastatin intensive treatment group(40mg/d) and routine treatment group(20mg/d). Admini-stration five days,two groups patients were observed blood lipid changes before and after treatment ,main cardiovasclular event performance and untoward effect incidence rate of adverse after 1-2weeks treatment.Result:The group of primary intensive atrovastatin therapy was significantly lower recidivity anqina ,heart failure, arrhyth-mia incidence rate than routine treatment group (p<0.05),without serious adverse reaction in two groups.Conclusion:Primary intensive atrovastatin therapy in the treatment of ACS can significantly lower recidivity anqina ,heart failure ,arrhythmia incidence rate in 1-2weeks after treatment and without serious adverse reaction.